From: The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature
Article | Type of study | Population | Results |
---|---|---|---|
Licup and Baumrucker, 2010 [26] | Literature review | Articles on the use of olanzapine as an antiemetic N = 4 | 2 articles on the use for chemotherapy-induced nausea and vomiting 2 articles on olanzapine in a palliative care setting Effective treatment No side effect reported |
Fonte et al, 2015 [10] | Literature review | Article on the use of olanzapine as an antiemetic N = 22 | 15 articles on the use of olanzapine for the treatment of chemotherapy-induced nausea and vomiting 7 articles on olanzapine in a palliative care setting Effective treatment No significant side effects, except sleepiness reported in some studies |
Felton et al, 2016 [27] | Literature review | Articles on the use of olanzapine in a palliative care population N = 12 | 2 articles on olanzapine for chemotherapy-induced nausea and vomiting 2 articles on olanzapine in a palliative care setting The other articles are on other indications Effective treatment No side effect reported |
Passik et al, 2002 [28] | Prospective single centre study | Hospitalized patients with advanced cancer and refractory nausea and vomiting unrelated to radiotherapy or chemotherapy N = 15 | In terms of nausea: dose-response efficacy (from 2.5 to 10 mg/day) In terms of quality of life: overall improvement only in patients treated at 5 mg/day No significant difference in side effects between patients without treatment and patients treated with different dosages |
MacKintosch, 2016 [29] | Prospective single centre study | Hospitalized cancer patients with refractory nausea and vomiting N = 16 | 2 patients excluded due to treatment for less than 48 h Subjective evaluation: 13 patients (92%) reported improvement of symptoms 1 patient (7%) decided to stop treatment for excessive drowsiness |
Kaneishi et al, 2012 [30] | Retrospective study | Patients hospitalized in the palliative care unit and treated with olanzapine for nausea and vomiting related to malignant bowel obstruction N = 20 | Significant decrease in nausea score and frequency of vomiting after olanzapine treatment 18 patients (90%) reported a subjective improvement of nausea 2 patients (10%) reported excessive drowsiness 1 patient (5%) reported vertigo No decision to stop treatment despite symptoms |
Atkinson, 2014 [31] | Retrospective study | Hospitalized cancer patients with refractory nausea and vomiting N = 4 | Effective treatment Reduced use of rescue medication Reduced treatment cost No side effects reported |
Kaneishi et al, 2016 [32] | Retrospective multicentre study | Patients with advanced cancer hospitalized in the palliative care unit and treated with olanzapine for nausea and vomiting N = 108 | Doses ranged from 2.5 to 10 mg/day Average duration of treatment: 22 days (from 2 to 211 days) No efficacy or safety data reported. |
Jackson and Tavernier, 2003 [33] | Case series | Hospitalized patients with cancer and neurological conditions and refractory nausea and vomiting N = 6 | Effective treatment No side effects reported |
Srivastava et al, 2003 [34] | Case series | Hospitalized cancer patients with refractory nausea and vomiting N = 2 | Effective treatment No side effects reported |
Atreya and Datta, 2016 [35] | Case series | Patients with advanced cancer hospitalized in palliative care unit with refractory nausea and vomiting N = 3 | Effective treatment No side effects reported |
Suzuki et al, 2014 [36] | Case study | 1 patient with refractory nausea and vomiting after brain metastases from colorectal cancer | Effective treatment No side effects reported |
Langley-Degroot et al, 2015 [37] | Case study | 1 patient with refractory nausea and vomiting after dyskeratosis congenita | Effective treatment No side effects reported |